Related Experiment Video

Updated: Mar 25, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients

Tetsuya Yasunaka1, Fusao Ikeda, Nozomu Wada

  • 1Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Acta Medica Okayama
|February 23, 2016
PubMed

Insights

Entecavir (ETV) significantly reduces hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients over 35 with high viral load and positive HBeAg. ETV is recommended for HCC suppression in this high-risk group.

Area of Science:

  • Hepatology
  • Virology
  • Oncology

Background:

  • Chronic hepatitis B (CHB) is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC).
  • Identifying high-risk CHB patients and effective treatments is crucial for preventing HCC.
  • Antiviral therapy plays a key role in managing CHB and reducing HCC incidence.

Purpose of the Study:

  • To compare HCC incidence rates in CHB patients based on age, HBV DNA levels, HBeAg status, and antiviral treatment.
  • To evaluate the efficacy of entecavir (ETV) and lamivudine (LVD) in preventing HCC development.
  • To provide evidence-based recommendations for HCC prevention in CHB patients.

Main Methods:

  • A cohort study of 1,206 CHB patients treated at Okayama University Hospital and affiliated hospitals between 2011-2012.
  • Patients were grouped by age, HBV DNA levels (>4 log copies/mL), HBeAg status (positive/negative), and treatment (ETV, LVD, or no drug).
  • Median observation period was 1,687 days, with cumulative HCC incidence rates analyzed over 5 years.

Main Results:

  • Among 184 patients aged >35 with high HBV DNA and positive HBeAg, 5-year HCC incidence was 8.4% with ETV, 21.8% with LVD, and 26.4% with no treatment (p=0.013).
  • ETV treatment significantly reduced HCC incidence compared to LVD or no treatment in this subgroup.
  • In 237 patients aged >35 with high HBV DNA and negative HBeAg, 5-year HCC incidence was 14.6% with ETV and 13.9% with no treatment (p>0.05).

Conclusions:

  • Entecavir (ETV) treatment significantly suppresses HCC development in CHB patients aged over 35 with high HBV DNA and positive HBeAg.
  • ETV is recommended as a preferred antiviral therapy for HCC prevention in this specific high-risk CHB population.
  • Further research may explore optimal treatment strategies for CHB patients with negative HBeAg.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.0K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
738